

ORIGINAL ARTICLE

https://doi.org/10.1590/2177-6709.27.3.e2220290.oar

How to use the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) in orthodontic research

Isabela Coelho NOVAES¹ https://orcid.org/0000-0002-6613-3557

Luna Chagas CLEMENTINO¹
https://orcid.org/0000-0001-9904-9418
Carlos FLORES-MIR²
https://orcid.org/0000-0002-0887-9385
Leandro Silva MARQUES³
https://orcid.org/0000-0002-7089-8739
Paulo Antônio MARTINS-JÚNIOR¹ ⊠
https://orcid.org/0000-0002-1575-5364

Submitted: July 14, 2020 • Revised and accepted: December 28, 2020 important pauloa-martinsjunior@ufmg.br

How to cite: Novaes IC, Clementino LC, Flores-Mir C, Marques LS, Martins-Júnior PA. How to use the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) in orthodontic research. Dental Press J Orthod. 2022;27(3):e2220290.

Department of Child and Adolescent Oral Health, School of Dentistry, Federal University of Minas Gerais (Belo Horizonte, Minas Gerais, Brazil).
 Department of Orthodontics, University of Alberta (Edmonton, Alberta, Canada).
 Department of Pediatric Dentistry and Orthodontics, Federal University of Vales do Jequitinhonha e Mucuri (Diamantina, Minas Gerais, Brazil).

ABSTRACT

Introduction: Clinical trial protocols are essential documents that serve as a basis for research planning. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement aimed to increase the transparency and integrity of clinical trial protocols.

Objectives: This paper described the main aspects of the SPIRIT, highlighting the importance of using this guideline in Orthodontics.

Results: The SPIRIT is composed of 33 items and the diagram, which were presented and explained.

Conclusion: The use of the SPIRIT checklist must become essential to increase the transparency and integrity of more reliable and less biased clinical trials in orthodontic research, improving the quality of future publications in this field.

Keywords: Checklist. Clinical trials. Evidence-based dentistry. Guideline adherence. Orthodontics.

INTRODUCTION

Clinical trial protocols are essential documents that describe the rationale, aims, methods, ethical issues and dissemination plans of clinical trials, and serve as a basis for research planning.^{1,2} All clinical trials, including those performed in the area of Orthodontics, should be based on a complete and transparent protocol. High-quality protocols facilitate assessing adherence to scientific, ethical and safety issues before the beginning of the research; analyzing the conduct and monitoring; as well as checking the results after the completion of the study.³⁻⁵ In addition, a good protocol allows evaluation of the consistency between the final report and the original intention.⁶ As a consequence, the importance of protocols has been emphasized by journal editors, reviewers and researchers in diverse areas.^{4,7}

In 2007, a first meeting was held in which a group launched the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT).^{5,8} However, the first article describing this checklist was only published in 2013.³ The SPIRIT 2013 Statement was rigorously developed from two systematic reviews and a Delphi consensus process, and involved 115 experts from different areas.^{1,6,9} SPIRIT adhered to the ethical principles required by the 2008 Declaration of Helsinki, encompassed the items of protocols recommended by the guidance of the International Conference on Harmonisation, Good Clinical

Practice E6 guidance, and covered the registration requirements of the World Health Organization, the International Committee of Medical Journal Editors and legislation relating to ClinicalTrials.gov.⁷ The SPIRIT consisted of a list of 33 items and a diagram (Fig 1) and aimed to increase the transparency and integrity of clinical trial protocols, providing evidence-based guidance and facilitating the development of high-quality protocols.^{7,8} SPIRIT was not dedicated to prescribe how a study should be designed or conducted, but to help the researcher, including in the area of Orthodontics, to describe clearly and completely what is planned and to understand the main elements of a protocol.³

Another positive point is that several items from SPIRIT corresponded to items from the Consolidated Standards of Reporting Trials (CONSORT).^{10,11} It is important to emphasize that SPIRIT and CONSORT were constructed in a different and complementary way in the development of clinical trials. SPIRIT was developed to assist in the construction, planning and appraisal of protocols for interventional studies, acting as a guide to decrease errors in the design of the study and to avoid possible biases. On the other hand, CONSORT can be used for reporting the results of (already conducted) clinical trials. In addition, it was designed to assist in quality assessment of randomized controlled trials (RCTs) throughout their structure.¹¹ Since SPIRIT mirrored applicable items

	STUDY PERIOD							
	Enrolment	Allocation	Post-allocation					Close-out
TIMEPOINT**	-t1	0	t 1	t 2	t ₃	t 4	etc.	tx
ENROLMENT:								
Eligibility screen	Х							
Informed consent	Х							
[List other procedures]	Х							
Allocation		Х						
INTERVENTIONS:								
[Intervention A]								
[Intervention B]			Х		X			
[List other study groups]								
ASSESSMENTS:								
[List baseline variables]	х	х						
[List outcome variables]				X		x	etc.	Х
[List other data variables]			х	x	x	X	etc.	х

Figure 1: Example template of recommended content for the schedule of enrollment, interventions, and assessments*. Available at: *https://www.spirit-statement.org/sched-ule-of-enrolment-interventions-and-assessments/*.

*Recommended content can be displayed using various schematic formats. See SPIRIT 2013 Explanation and Elaboration for examples from protocols.

**List specific timepoints in this row.

from CONSORT, it became simpler to make the transition from a protocol based on SPIRIT to a final report based on CONSORT.^{3,5} The 33 items of SPIRIT were distributed in 5 categories, as follows:

ADMINISTRATIVE INFORMATION (ITEMS 1-5)

The protocol should present a descriptive title identifying the study design, population and interventions; the trial registration; the protocol version; the date and version identifier; the funding and the roles and responsibilities, when applicable. For example, an adequate title should describe which types of brackets (conventional or self-ligating) were tested in what profile of patients (adolescents) to evaluate what kind of outcomes (arch dimensional changes).

INTRODUCTION (ITEMS 6-8)

A description of the research question and the justification for conducting the trial should be made considering the benefits and harms for each intervention. The choice of comparators should be explained. The aims and hypotheses should be clarified, and the clinical trial design should be described. For example, a trial comparing two types of treatment for debilitating malocclusions should clearly describe the rationale for conducting the study, explaining the advantages and limitations of each treatment modality, as well as what authors expected to find.

METHODS (ITEMS 9-23)

8

- Participants, interventions and outcomes (items 9-15): } The researcher should write the study settings and specify eligibility criteria (inclusion and exclusion). For interventions, each study group should present details that allow replication, explain the criteria for interruption/modification of interventions to participants; and present strategies for improving adherence. The protocol should describe all outcomes, including the specific measurement variable, analysis metrics, and method of aggregation. It is essential to inform the recruitment period, interventions, evaluations and visits for participants. It should contain a description of the sample calculation and recruitment strategies of the participants. For example, in a trial comparing the effects of orthodontic treatment on the oral health-related quality of life of adolescent patients, it should describe in details where, when and how recruitment was carried out.
- » Assignment of interventions (for controlled trials) (items 16-17): The protocol should describe the method used to generate the allocation sequence and the list for stratification factors. It should provide planned restrictions (to reduce the predictability of a randomized sequence) in a separate document, unavailable to those responsible for participant registration. It needs to specify the allocation concealment mechanism used until the assignment of interventions is carried out. Also, the responsible for

generating the allocation sequence, registering participants, and assigning participants to the interventions needs to be described. On blinding, the protocol should identify who will be blinded after assignment to interventions and how this will be done. If blind, it is needed to describe the circumstances under which unblinding is permissible, and the procedure for revealing the participant's intervention during the trial. For example, a trial comparing two drugs for pain control after fixed orthodontic appliance placement should clearly describe how randomization was conducted: using opaque, labeled, and sealed envelopes or trough a website/software. In addition, it should be informed whether a single (patient), double (patient and clinician) or triple (patient, clinician and statistician) blinding was achieved.

» Data collection, management and analysis (items 18-20): The protocol should describe evaluation plans for evaluation and outcome collection, baseline, and other trial data, description of study instruments (including reliability and validity), and reference to where data collection forms can be found. The plans for promoting participant retention and complete follow-up, including a list of outcome data of those who discontinue the protocols, should be described. Its should inform plans for data entry, encoding, security, and storage. Reference to the location of information on data management procedures should be included.

Statistical methods for analyzing primary and secondary results should also be included. Methods for any additional analyses, definition of the analysis population for non-adherence to the protocol and statistical methods for dealing with missing data should be included. Following the example given above about a trial comparing the effects of orthodontic treatment on the oral health-related quality of life of adolescent patients, it should be described whether the instrument used to measure quality of life of patients was translated and validated for use in the country where the study was carried out, how it is applied (self-applicable or interview) and how scores are interpreted (higher scores denote poorer quality of life?). Data analysis plan, including use of parametric or non-parametric tests, bivariate or multivariate analysis, must be informed.

Monitoring (items 21-23): The protocol should present the composition of the data monitoring committee, the summary of its role, the reporting structure, the statement about its independence from the sponsor and competing interests, and the reference to where more details about the data can be found. It should describe the interim analyses and interruption guidelines. In relation to harm, plans for the collection, assessments, reporting/management of requested and spontaneously reported adverse events and other unintended effects of conducting the trial should be reported. If applicable, it should state the frequency

and audit procedures for conducting the trial. Following the example given above about the use of two drugs for pain relief after initial orthodontic treatment, researchers need to clarify how monitoring of side, harmful, undesirable effects would occur and how reporting would be conducted and the protocol for trial interruption.

ETHICS AND DISCLOSURE (ITEMS 24-31)

11

The protocol should describe plans for obtaining approval from the Research Ethics Committee/Institutional Review Committee or, if the research is already approved, inform its protocol number. The plans for communicating important protocol changes to relevant parties should be described. It should inform who will obtain consent/assent from prospective trial participants or authorized surrogates, and how it will be conducted. If necessary, it should inform consent for collection and use of data and biological samples from participants. An important point is to describe how personal information of participants will be collected, shared and maintained. The declarations of interest and who will have access to the final trial data set should be presented. It should disclose the contractual agreements that limit this access to the researchers. If they exist, auxiliary care, post-trial and indemnification to the participant who may have suffered damages should be reported. Regarding the dissemination policy, it should mention how the results will be communicated to interest groups, author eligibility guidelines and plans for granting public access to the full protocol, the participant-level data set and the statistical code. For example, in a trial involving evaluation of orthodontic treatment in children and adolescents, it must be stated the obtainment of informed consent from both patients and parents/guardians.

APPENDICES (ITEMS 32-33)

12

The protocol should present the consent form and other documentation related to the participants and authorized surrogates. Plans for collection, laboratory evaluation, and storage of biological samples for genetic or molecular analysis in the current study and for future use should be presented. For example, in a trial that needs to collect saliva, crevicular fluid or blood for biochemical analyses in patients undergoing fixed orthodontic appliance treatment, a document with detailed information about use and storage of these biological samples should be presented.

SPIRIT also has two extensions, which provide specific guidance for protocols related to patient-reported outcomes (PROs)² and for Traditional Chinese Medicine.¹² The SPIRIT-PRO extension was developed according to the methodological structure of EQUATOR, and provided international guidance based on consensus about specific PRO information that should be included in clinical trial protocols, such as health-related

quality of life or patient-reported symptoms. It consisted of 16 items and aimed to encourage and facilitate the careful planning about the use of PRO components in trials, improving the experimental design.²

Following the recommendations of the EQUATOR network, several scientific journals already require that submitted protocol articles should comply with SPIRIT, such as the BMC Oral Health, Medicine (Baltimore), and Trials.^{4,7} Interested researchers can use a website (*https://www.spirit-statement.org/trial-protocol-template/*) to create, manage, and register protocols in *clinicaltrials.gov* using the SPIRIT guidance. It should be stated that Brazilians should register trials in the *Registro Brasileiro de Ensaios Clínicos* (ReBEC) (*www.ensaiosclinicos.gov.br*). After submission, the protocols will receive a registration number and will be evaluated by a specific committee. It is important to note that not all items need to be strictly followed. Also, some items can be suppressed, according to trial characteristics.

Both researchers and clinical orthodontists can take advantage of using SPIRIT. Researchers can use SPIRIT to construct high-quality, efficient, and transparent protocols. Clinicians can use SPIRIT to evaluate protocols of clinical trials in orthodontic research. The popularization and application of SPIRIT is indispensable in Orthodontics and should occur as quickly as possible, since an exponential increase in clinical trials is taking place. In conclusion, the development of better and more transparent protocols based on SPIRIT checklist results in ease of conducting the study, reduction of avoidable errors and associated costs, and increases the quality and efficiency of the protocol review. Consequently, these benefits will be translated into higher-quality, more reliable and less biased clinical trials.

AUTHORS' CONTRIBUTIONS

Isabela Coelho Novaes (ICN)

Luna Chagas Clementino (LCC)

Carlos Flores-Mir (CFM)

15

Leandro Silva Marques (LSM)

Paulo Antônio Martins-Júnior (PAMJ)

Conception or design of the study: LSM, PAMJ. Data acquisition, analysis or interpretation: ICN, LCC, CFM, LSM, PAMJ. Writing the article: ICN, LCC, CFM, LSM, PAMJ. Critical revision of the article: ICN, LCC, CFM, LSM, PAMJ. Final approval of the article: ICN, LCC, CFM, LSM, PAMJ. Overall responsibility: PAMJ.

The authors report no commercial, proprietary or financial interest in the products or companies described in this article.

REFERENCES

- 1. Agha RA, Altman DG, Rosin D. The SPIRIT 2013 statement: defining standard protocol items for trials. Int J Surg. 2015 Jan;13:288-91.
- Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA. 2018 Feb;319(5):483-94.
- 3. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan;346:e7586.
- Tetzlaff JM, Chan AW, Kitchen J, Sampson M, Tricco AC, Moher D. Guidelines for randomized clinical trial protocol content: a systematic review. Syst Rev. 2012 Sep;1:43.
- Schulz KF, Grimes DA. Get in the spirit with SPIRIT 2013: protocol content guideline for clinical trials. Contraception. 2013 Dec;88(6):676-7.
- Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT
 2013: new guidance for content of clinical trial protocols. Lancet.
 2013 Jan;381(9861):91-2.
- Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb;158(3):200-77.

- Tetzlaff JM, Moher D, Chan AW. Developing a guideline for clinical trial protocol content: delphi consensus survey. Trials. 2012 Sep;13:176.
- 9. Dutton SJ. The SPIRIT 2013 statement. Maturitas. 2014;78(1):1-2.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT
 2010 statement: updated guidelines for reporting parallel group
 randomised trials. BMJ. 2010 Mar;340:c332.
- 11. Falci SG, Marques LS. CONSORT: when and how to use it. Dental Press J Orthod. 2015;20(3):13-5.
- Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, et al. Standard protocol items for clinical trials with traditional chinese medicine 2018: recommendations, explanation and elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019 Jan;25(1):71-9.